Goldman Sachs Maintains Buy on Calumet, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Neil Mehta maintains a Buy rating on Calumet (NASDAQ:CLMT) but lowers the price target from $17 to $15.
August 05, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs analyst Neil Mehta maintains a Buy rating on Calumet but lowers the price target from $17 to $15.
The maintained Buy rating suggests continued confidence in Calumet's performance, but the lowered price target indicates a more cautious outlook on its short-term valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100